Hyperglycemia and Antipsychotic Medications
J Clin Psychiatry 2001;62(suppl 27):15-26
© Copyright 2015 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Type 2 diabetes mellitus and impaired glucose tolerance are associated with antipsychotic treatment.
Risk factors for type 2 diabetes and impaired glucose tolerance include abdominal adiposity,
age, ethnic status, and certain neuropsychiatric conditions. While impaired glucose metabolism was
first described in psychotic patients prior to the introduction of antipsychotic medications, treatment
with antipsychotic medications is associated with impaired glucose metabolism, exacerbation of existing
type 1 and 2 diabetes, new-onset type 2 diabetes mellitus, and diabetic ketoacidosis, a severe
and potentially fatal metabolic complication. The strength of the association between antipsychotics
and diabetes varies across individual medications, with the largest number of reports for chlorpromazine,
clozapine, and olanzapine. Recent controlled studies suggest that antipsychotics can impair glucose
regulation by decreasing insulin action, although effects on insulin secretion are not ruled out.
Antipsychotic medications induce weight gain, and the potential for weight gain varies across individual
agents with larger effects observed again for agents like chlorpromazine, clozapine, and olanzapine.
Increased abdominal adiposity may explain some treatment-related changes in glucose metabolism.
However, case reports and recent controlled studies suggest that clozapine and olanzapine
treatment may also be associated with adverse effects on glucose metabolism independent of adiposity.
Dyslipidemia is a feature of type 2 diabetes, and antipsychotics such as clozapine and olanzapine
have also been associated with hypertriglyceridemia, with agents such as haloperidol, risperidone, and
ziprasidone associated with reductions in plasma triglycerides. Diabetes mellitus is associated with
increased morbidity and mortality due to both acute (e.g., diabetic ketoacidosis) and long-term (e.g.,
cardiovascular disease) complications. A progressive relationship between plasma glucose levels and
cardiovascular risk (e.g., myocardial infarction, stroke) begins at glucose levels that are well below
diabetic or “impaired” thresholds. Increased adiposity and dyslipidemia are additional, independent
risk factors for cardiovascular morbidity and mortality. Patients with schizophrenia suffer increased
mortality due to cardiovascular disease, with presumed contributions from a number of modifiable
risk factors (e.g., smoking, sedentary lifestyle, poor diet, obesity, hyperglycemia, and dyslipidemia).
Patients taking antipsychotic medications should undergo regular monitoring of weight and plasma
glucose and lipid levels, so that clinicians can individualize treatment decisions and reduce iatrogenic
contributions to morbidity and mortality.